Previous 10 | Next 10 |
EMERYVILLE, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Michael Smith, Executive Vice President, Chief Financial Officer, and Treasurer, will present a corpo...
Zogenix, Inc. (ZGNX) Q4 2020 Earnings Conference Call February 25, 2021, 16:30 ET Company Participants Brian Ritchie - LifeSci Advisors Stephen Farr - Co-Founder, CEO, President & Director Ashish Sagrolikar - EVP & Chief Commercial Officer Michael Smith - EVP, CFO & Treasurer Conf...
Zogenix (ZGNX): Q4 GAAP EPS of $1.26 beats by $2.26.Revenue of $8.5M (+335.9% Y/Y) beats by $1.21M.Ended 2020 with $505.1M in cash, cash equivalents and marketable securities.Planned New Drug Application submission in 1H22 for MT1621 in TK2 deficiencyPress Release For further details see: ...
Positive momentum continues for U.S. launch of FINTEPLA ® (fenfluramine) oral solution in Dravet syndrome, with total net product sales of $8.1 million in the fourth quarter; total net sales of $9.6 million since launch in July 2020 As of December 31, 2020, ...
EMERYVILLE, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D., will participate in a fireside chat on Friday, February 26, 2021, at the 10 th Annual SVB Leer...
EMERYVILLE, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2020 and host a corporate upd...
Our last look at Zogenix was in March of last year. Recently, another name in the company's space, GW Pharma was acquired for over $7 billion. Quite a bit has happened with the company since we last visited it. So, it is time to update our investment thesis on Zogenix to account for r...
Jazz Pharmaceuticals (JAZZ) has been talking to GW Pharmaceuticals (GWPH) for "a bit" of time before deal announced today, CNBC's David Faber said."They've looked at this deal for quite some time is my understanding, been talking for a bit," Faber said. "Unclear whether there was any sor...
Zogenix (ZGNX) climbing 18% in premarket trading on a positive read through from Jazz Pharmaceuticals' (JAZZ) $7.2b planned purchase of GW Pharmaceuticals (GWPH).The deal values GWPH at 9.4x EV/consensus 2021 estimated sales and if one applies a similar multiple for Zogenix it gets to a...
SELLAS Life Sciences (SLS) +60%.Tyme Technologies (TYME +57% as the company granted U.S. patent claims covering use of TYME-19.10X Capital Venture Acquisition (VCVCU +48% on plans to take Israeli electric-vehicle technology company REE Automotive public through a merg...
News, Short Squeeze, Breakout and More Instantly...
UCB Completes Acquisition of Zogenix, Inc. - Broadens and builds upon UCB's role as a leader in, and our continued commitment to, addressing unmet needs of people living with epilepsy - Total transaction value of up to approximately US$ 1.9 billion / € 1.7 billion. Th...
Zogenix Inc. (NASDAQ:ZGNX) traded today at a new 52-week high of $26.66. Approximately 1.2 million shares have changed hands today, as compared to an average 30-day volume of 3.7 million shares. Zogenix Inc. (NASDAQ:ZGNX) defies analysts with a current price ($26.57) 0.4% above its avera...
Two podium and one poster presentation share important new findings on FINTEPLA’s safety profile and its impact on non-seizure related benefits for LGS patients LGS is a debilitating childhood-onset developmental and epileptic encephalopathy estimated to affect approx...